Vaccines and Immunological Agents

78 Drugs classified under this therapeutic system

Bacterial and Viral Vaccines. RSV F antigen, A+B subgroups 60+60 mcg/ 0.5 ml.
Powder and solv. for sol. for IM inject. (60+60 mcg/vial) 1/5/10 doses
A sgle. dose of 0.5 ml to be admin to pregn. women between weeks 24-36  and to persons aged >60. See lit.
• Pass. protect.against lower respir. tract dis. caused by respir. syncytial virus (RSV) in infants from birth through 6 mo. of age following maternal immunisat. during pregn. • Active immunisat. of 60 years of age and older for the prevent. of lower respir. tract disease caused by RSV.
C/I: Hypersens.

Haemophilus Influenzae type b 10 mcg / 0.5 ml.
VIALS: (pwdr.) 1 + syringe: 0.5 ml. I.M or
S.C. route. See lit.
Prevent. in inf. against invas. dis.
caused by H. influenza type B such as
meningit., septicem., cellulit., arthrit.,
epiglotit.
C/I: Hypersens., espec. tetanus protein.

Tetanus Toxoid 5 Lf, Diphtheria Toxoid 2 Lf, Pertussis Toxoid 2.5 mcg, Filamentous Haemagglutinin 5 mcg, Pertactin 3 mcg, Fimbriae Types 2+3 5 mcg.
Cont. in 0.5 ml :
Diphtheria Toxoid 2 Lf ;Tetanus Toxoid 5 Lf ;
Pertussis Toxoid 2.5 microg; Filamentous Haemagglutinin 5 microg;
Pertactin 3 microg; Fimbriae Types 2 and 3 5 microg;
Aluminium (aluminium phosphate by calc.) 0.33 mg (1.5mg)
VIAL: 1/5/10 x 0.5 ml. susp for I.M.  inj. into deltoid musc.
 Immun. schedule as per health auth. recommen. Re-dosing at 5-10 years  interval. See lit.
 Active booster immun. for the prevent. of tetanus, diphtheria and pertussis in childr, adolesc. and adlts aged 4 to 64 years. Not for use as dis. tmt.
C/I:Hypersens. Encephalopathy of unknown origin within 7 days of prev. immuniz. with a pertussis-cont. vacc. To be postponed in persons suffering from an ac. sev. febrile illness. Minor infect. is not a contraind.

Diphtheria Toxoid Not less than 2 IU, Tetanus Immuneglobulin 5 Lf, Pertussis Toxoid 2.5 mcg, Filamentous Haemagglutinin 5 mcg, Fimbriae Types 2+3 5 mcg, Pertactin 3 mcg, Poliomyelitis Virus Type 1 40 D-antigen units, Poliomyelitis Virus Type 2 8 D-antigen units, Poliomyelitis Virus Type 3 32 D-antigen units.
PRE-FILLED SYRINGES (susp. for inject.):
1, 10, 20. Starting from age 3, a single
I.M. 0.5 ml dose, in deltoid muscle,
applies to all age groups.
Active booster immunisat. for prevent.
diphth., tetanus, pertussis and polio,
from 3 yrs and over.
C/I: Hypersens., anaphylact./allerg.
reacts. to similar vaccine,
encephalopath. of unknown origin
within 7 days of prev. immunisat. dose
of any vaccine cont. pertussis antigens
(whole cell or acellular). Progress.
neurolog. disords., uncontroll. epilepsy,
progress. encephalopath. until tmt.
regimen established. Febrile or acute
illness. See lit.

Respiratory Syncytial Virus (RSV) vaccine. Respiratory Syncytial Virus recombinant glycoprotein F antigen 120 mcg/ 0.5 ml.
1/10 X Powder and susp. for IM inject. to obtain 0.5 ml dose
 To be admin. as a single dose of 0.5 mL.
The need for revaccination has not been established.
 Active immunisation for the prevention of lower respir. tract dis. (LRTD) caused by respir. syncytial virus in adults> 60 and adults 50 through 59 years of age who are at incr. risk for RSV dis.
C/I:  Hypersens.

Hepatitis A Virus Antigen (Inactivated) 80 U / 0.5 ml.
SUSP. FOR INJECT. (single dose prefilled
syringe): 1. Prim. vaccinat: 0.5 ml.
Booster within 6-8 mths. foll. initial dose.
I.M. in deltoid. See lit.
SUSP. FOR INJECT. (multidose vial): 10 x
0.5 ml. As above
Active immunizat. against hepatit. A
virus in child 12 mths-15 yrs (inclus.).
C/I: Hypersens. to active ingred.,
neomycin, polysorbate, foll. prev. inject.
Feber, acute/chron. evolv. dis. See lit.